Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease  Shounak Majumder, Sonmoon Mohapatra, Ryan J. Lennon, Guilherme Piovezani Ramos, Neil Postier, Ferga C. Gleeson, Michael J. Levy, Randall K. Pearson, Bret T. Petersen, Santhi Swaroop Vege, Suresh T. Chari, Mark D. Topazian, Thomas E. Witzig  Clinical Gastroenterology and Hepatology  Volume 16, Issue 12, Pages 1947-1953 (December 2018) DOI: 10.1016/j.cgh.2018.02.049 Copyright © 2018 AGA Institute Terms and Conditions

Figure 1 Kaplan–Meier curves showing the difference in relapse rates between groups after completion of rituximab induction therapy (time 0). Clinical Gastroenterology and Hepatology 2018 16, 1947-1953DOI: (10.1016/j.cgh.2018.02.049) Copyright © 2018 AGA Institute Terms and Conditions

Figure 2 Kaplan–Meier curves showing the difference in relapse rates between groups after the last rituximab infusion (time 0). Clinical Gastroenterology and Hepatology 2018 16, 1947-1953DOI: (10.1016/j.cgh.2018.02.049) Copyright © 2018 AGA Institute Terms and Conditions

Figure 3 Kaplan–Meier curves showing the difference in relapse rates between patients with normal serum alkaline phosphatase (ALP) concentrations and patients with pretreatment alkaline phosphatase concentration increases that normalized after induction therapy or were persistently abnormal. RTX, rituximab. Clinical Gastroenterology and Hepatology 2018 16, 1947-1953DOI: (10.1016/j.cgh.2018.02.049) Copyright © 2018 AGA Institute Terms and Conditions